FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217363670> ?p ?o ?g. }

• W3217363670 endingPage "4961" @default.
• W3217363670 startingPage "4961" @default.
• W3217363670 abstract "Abstract New classes of therapies have emerged for treating Relapsed or Refractory Multiple Myeloma (RRMM) patients, including chimeric antigen receptor T-cell (CAR-T) therapies targeting the B-cell maturation antigen. While CAR-T therapies are expected to be a more expensive class of treatment compared to chemotherapy, 1 they have been shown to have a high overall response rate (ORR) and progression-free survival (PFS). 2,3 As newer, more innovative RRMM therapies are developed and brought to market, payers will need to balance their higher efficacy and total treatment costs when assessing potential value. To assess the value of RRMM CAR-T therapies (ciltacabtagene autoleucel [cilta-cel] and idecabtagene vicleucel [ide-cel]), we developed a cost per responder (CPR) model that incorporates efficacy and total cost of treatment. In the absence of head-to-head trial data for CAR-T therapies, indirect treatment comparisons (ITCs) can be used to evaluate comparative efficacy, and the results can be used to inform a CPR model. Matching-adjusted indirect comparisons (MAIC) is a form of ITC that involves matching and adjusting a treatment group from a clinical study with individual patient-level data (IPD) available to a comparator for which only summary-level data are available. This method mitigates potential bias arising from differences in patient characteristics between trials and is widely used and accepted in comparative effectiveness research. Unanchored matching adjusted indirect comparison (MAIC) analyses were used to inform the comparative efficacy of cilta-cel versus ide-cel in our CPR model. MAIC results indicated that cilta-cel was associated with statistically significantly improved ORR (odds ratio [OR]: 87.99 [95% confidence interval [CI]: 20.32, 381.01; p &lt; .0001]), complete response or better (≥CR) rate (OR: 5.96 [95% CI: 2.76, 12.88; p &lt; .0001]) and PFS (hazard ratio [HR]: 0.36 [95% CI: 0.22, 0.59; p &lt; .0001]) when compared with ide-cel. 4 To adequately capture total treatment costs for each treatment of interest, CPR models should include all costs related to acquisition and delivery of treatment. Relevant costs of CAR-T therapy for RRMM include the cost of apheresis, bridging therapy, costs of CAR-T acquisition and administration, supportive care and monitoring costs, adverse event management costs, and any costs associated with delivery of inpatient or outpatient clinical services. Preliminary results of the CPR analysis indicate that ide-cel is associated with a cost per ORR of approximately $743,000, a cost per CR or better of $1.66 million and a cost per month in PFS of approximately $55,000. Corresponding results for cilta-cel will be generated after the PDUFA date (November 29, 2021), and presented at ASH 2021. In conclusion, CPR models have significant potential to assist payers in evaluating the value of newer, more innovative RRMM therapies by integrating information on both total costs and efficacy. References 1 Pagliarulo N. FDA approves first CAR-T cell therapy for multiple myeloma. https://www.biopharmadive.com/news/fda-car-t-multiple-myeloma-approval-bristol-myersbluebird/597438/#:~:text=The%20pharma%2C%20which%20licensed%20the,other%20approve d%20CAR%2DT%20therapies. Published 27 March 2021. Accessed 22 June 2021. 2 Munshi NC, Anderson Jr LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-16. 3 Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in relapsed/refractory multiple myeloma [abstract]. Blood. 2020;136(1 supplement). Abstract 177. 4 Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC et al. (2021) Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 1-10. Disclosures Martin: Sanofi: Research Funding; Oncopeptides: Consultancy; Janssen: Research Funding; Amgen: Research Funding; GlaxoSmithKline: Consultancy. Usmani: Pharmacyclics: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Merck: Consultancy, Research Funding; SkylineDX: Consultancy, Research Funding; Bristol-Myers Squibb: Research Funding; Takeda: Consultancy, Research Funding, Speakers Bureau; Janssen Oncology: Consultancy, Research Funding; Abbvie: Consultancy; Array BioPharma: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding, Speakers Bureau; Celgene/BMS: Consultancy, Research Funding, Speakers Bureau; GSK: Consultancy, Research Funding; EdoPharma: Consultancy; Janssen: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau. Joseph: Johnson and Johnson: Current Employment, Current equity holder in publicly-traded company. Crivera: Johnson & Johnson: Current Employment, Current equity holder in publicly-traded company. Valluri: Janssen: Current Employment, Current equity holder in publicly-traded company. Jackson: Memorial Sloan Kettering Cancer Center: Consultancy; Janssen: Current Employment. Cohen: Eversana Life Science Services: Current Employment, Other: Eversana Life Science Services was contracted by Janssen to work on this project.. Singh: Eversana Life Science Services: Current Employment, Other: Eversana Life Science Services was contracted by Janssen to work on this project.." @default.
• W3217363670 created "2021-12-06" @default.
• W3217363670 creator A5009026971 @default.
• W3217363670 creator A5009378735 @default.
• W3217363670 creator A5017822896 @default.
• W3217363670 creator A5028046297 @default.
• W3217363670 creator A5043040581 @default.
• W3217363670 creator A5062185552 @default.
• W3217363670 creator A5068416260 @default.
• W3217363670 creator A5077169512 @default.
• W3217363670 creator A5087850384 @default.
• W3217363670 date "2021-11-05" @default.
• W3217363670 modified "2023-10-01" @default.
• W3217363670 title "Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma" @default.
• W3217363670 doi "https://doi.org/10.1182/blood-2021-146237" @default.
• W3217363670 hasPublicationYear "2021" @default.
• W3217363670 type Work @default.
• W3217363670 sameAs 3217363670 @default.
• W3217363670 citedByCount "0" @default.
• W3217363670 crossrefType "journal-article" @default.
• W3217363670 hasAuthorship W3217363670A5009026971 @default.
• W3217363670 hasAuthorship W3217363670A5009378735 @default.
• W3217363670 hasAuthorship W3217363670A5017822896 @default.
• W3217363670 hasAuthorship W3217363670A5028046297 @default.
• W3217363670 hasAuthorship W3217363670A5043040581 @default.
• W3217363670 hasAuthorship W3217363670A5062185552 @default.
• W3217363670 hasAuthorship W3217363670A5068416260 @default.
• W3217363670 hasAuthorship W3217363670A5077169512 @default.
• W3217363670 hasAuthorship W3217363670A5087850384 @default.
• W3217363670 hasBestOaLocation W32173636701 @default.
• W3217363670 hasConcept C112930515 @default.
• W3217363670 hasConcept C121608353 @default.
• W3217363670 hasConcept C126322002 @default.
• W3217363670 hasConcept C143998085 @default.
• W3217363670 hasConcept C2776364478 @default.
• W3217363670 hasConcept C2777701055 @default.
• W3217363670 hasConcept C3019080777 @default.
• W3217363670 hasConcept C3875195 @default.
• W3217363670 hasConcept C535046627 @default.
• W3217363670 hasConcept C71924100 @default.
• W3217363670 hasConceptScore W3217363670C112930515 @default.
• W3217363670 hasConceptScore W3217363670C121608353 @default.
• W3217363670 hasConceptScore W3217363670C126322002 @default.
• W3217363670 hasConceptScore W3217363670C143998085 @default.
• W3217363670 hasConceptScore W3217363670C2776364478 @default.
• W3217363670 hasConceptScore W3217363670C2777701055 @default.
• W3217363670 hasConceptScore W3217363670C3019080777 @default.
• W3217363670 hasConceptScore W3217363670C3875195 @default.
• W3217363670 hasConceptScore W3217363670C535046627 @default.
• W3217363670 hasConceptScore W3217363670C71924100 @default.
• W3217363670 hasIssue "Supplement 1" @default.
• W3217363670 hasLocation W32173636701 @default.
• W3217363670 hasOpenAccess W3217363670 @default.
• W3217363670 hasPrimaryLocation W32173636701 @default.
• W3217363670 hasRelatedWork W2384208351 @default.
• W3217363670 hasRelatedWork W2914133986 @default.
• W3217363670 hasRelatedWork W2984166065 @default.
• W3217363670 hasRelatedWork W3036257999 @default.
• W3217363670 hasRelatedWork W3139396124 @default.
• W3217363670 hasRelatedWork W3204581877 @default.
• W3217363670 hasRelatedWork W4210470883 @default.
• W3217363670 hasRelatedWork W4312116120 @default.
• W3217363670 hasRelatedWork W4320006233 @default.
• W3217363670 hasRelatedWork W4360824654 @default.
• W3217363670 hasVolume "138" @default.
• W3217363670 isParatext "false" @default.
• W3217363670 isRetracted "false" @default.
• W3217363670 magId "3217363670" @default.
• W3217363670 workType "article" @default.